Nov. 12, 2025QEL-005 restores homeostasis in inflammatory disordersQuell Therapeutics Ltd. have presented data for QEL-005, a new CAR Treg-based compound that targets CD19 and contains a FOXP3 phenotype lock.
Nov. 11, 2025NKX-019 induces CD19 depletion in autoimmune diseaseNkarta Therapeutics Inc. has recently presented data for their allogeneic CAR natural killer (NK) cell therapy, NKX-019, targeting CD19 for treating autoimmune disease through B-cell targeting.
Nov. 10, 2025CDR-Life’s new dual-targeting T-cell engagerCDR-Life Inc. has presented data on the preclinical characterization of CDR-111, a CD19/BCMA dual T-cell engager for treating autoimmune diseases.
